-+ 0.00%
-+ 0.00%
-+ 0.00%

Lexaria Bioscience Completes Blood Plasma Pharmacokinetic Bioanalysis Testing In Its 2026 Animal Study 2 Evaluating Oral Delivery Of 2 Next-Generation GLP-Drugs, Amycretin And Retatrutide, In A Total Of 18 Different Study Arms In Dogs Following Use Of Its DehydraTECH Drug Delivery Platform

Benzinga·08/24/2026 13:14:25
Listen to the news

Proprietary DehydraTECH 3.0 amycretin tablet formulation more than doubled absolute bioavailability compared to a leading industry study

Proprietary DehydraTECH 3.0 retatrutide tablet formulation increased drug absorption by as much as an astonishing 4,552% compared to the DehydraTECH 2.0 retatrutide tablet evaluated

Findings support Lexaria's expanding strategic partnering outreach activities by evidencing DehydraTECH benefits for oral delivery of next generation GLP-1 drugs